SI3705488T1 - Nevroaktivni steroidi, sestavki in uporaba le-teh - Google Patents
Nevroaktivni steroidi, sestavki in uporaba le-tehInfo
- Publication number
- SI3705488T1 SI3705488T1 SI201531879T SI201531879T SI3705488T1 SI 3705488 T1 SI3705488 T1 SI 3705488T1 SI 201531879 T SI201531879 T SI 201531879T SI 201531879 T SI201531879 T SI 201531879T SI 3705488 T1 SI3705488 T1 SI 3705488T1
- Authority
- SI
- Slovenia
- Prior art keywords
- compositions
- neuroactive steroids
- neuroactive
- steroids
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 150000003431 steroids Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
- C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
- C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/009—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by only one oxygen atom doubly bound
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2014078820 | 2014-05-29 | ||
EP20171670.1A EP3705488B1 (en) | 2014-05-29 | 2015-05-29 | Neuroactive steroids, compositions and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SI3705488T1 true SI3705488T1 (sl) | 2022-10-28 |
Family
ID=54698130
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201531879T SI3705488T1 (sl) | 2014-05-29 | 2015-05-29 | Nevroaktivni steroidi, sestavki in uporaba le-teh |
SI201531252T SI3149018T1 (sl) | 2014-05-29 | 2015-05-29 | Nevroaktivni steroidi, sestavki in uporaba le-teh |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201531252T SI3149018T1 (sl) | 2014-05-29 | 2015-05-29 | Nevroaktivni steroidi, sestavki in uporaba le-teh |
Country Status (26)
Country | Link |
---|---|
US (5) | US20180179247A1 (sl) |
EP (3) | EP3149018B1 (sl) |
JP (4) | JP6652934B2 (sl) |
KR (2) | KR20240066304A (sl) |
CN (3) | CN114133423A (sl) |
AR (2) | AR100691A1 (sl) |
AU (4) | AU2015266447A1 (sl) |
CA (1) | CA2949720A1 (sl) |
CY (1) | CY1124109T1 (sl) |
DK (2) | DK3705488T3 (sl) |
ES (2) | ES2927007T3 (sl) |
HR (2) | HRP20221294T1 (sl) |
HU (2) | HUE059829T2 (sl) |
IL (3) | IL292461B2 (sl) |
JO (1) | JO3691B1 (sl) |
LT (2) | LT3149018T (sl) |
MX (4) | MX2016015532A (sl) |
PH (1) | PH12016502342A1 (sl) |
PL (2) | PL3149018T3 (sl) |
PT (2) | PT3149018T (sl) |
RS (2) | RS63554B1 (sl) |
RU (2) | RU2019126637A (sl) |
SG (2) | SG11201609813XA (sl) |
SI (2) | SI3705488T1 (sl) |
TW (1) | TW201625661A (sl) |
WO (1) | WO2015180679A1 (sl) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101405545B1 (ko) | 2005-11-28 | 2014-07-03 | 마리누스 파마슈티컬스 | ganaxolone 제형, 이의 제조방법 및 용도 |
CA3152410A1 (en) | 2011-10-14 | 2013-04-18 | Sage Therapeutics, Inc. | 3,3-disubstituted 19-nor pregnane compounds, compositions, and uses thereof for the treatment of cns related disorders |
US20160068563A1 (en) | 2013-04-17 | 2016-03-10 | Boyd L. Harrison | 19-nor neuroactive steroids and methods of use thereof |
CN112110976B (zh) | 2013-04-17 | 2023-08-29 | 萨奇治疗股份有限公司 | 刺激神经活性的19-去甲类固醇及其使用方法 |
US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
CN113527400A (zh) | 2013-04-17 | 2021-10-22 | 萨奇治疗股份有限公司 | 19-去甲c3,3-二取代的c21-n-吡唑基类固醇及其使用方法 |
LT3021852T (lt) | 2013-07-19 | 2021-04-12 | Sage Therapeutics, Inc. | Neuroaktyvūs steroidai, jų kompozicijos ir panaudojimas |
DK3488852T3 (da) | 2013-08-23 | 2021-02-01 | Sage Therapeutics Inc | Neuroaktive steroider, sammensætninger og anvendelser deraf |
SI3705488T1 (sl) * | 2014-05-29 | 2022-10-28 | Sage Therapeutics, Inc. | Nevroaktivni steroidi, sestavki in uporaba le-teh |
WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
ES2808855T3 (es) | 2014-10-16 | 2021-03-02 | Sage Therapeutics Inc | Composiciones y métodos para tratar trastornos del SNC |
TW202235090A (zh) | 2014-10-16 | 2022-09-16 | 美商賽吉醫療公司 | 用於治療中樞神經系統(cns)病症之組合物及方法 |
WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
HUE054092T2 (hu) | 2015-01-26 | 2021-08-30 | Sage Therapeutics Inc | Központi idegrendszeri zavarok kezelésére szolgáló kompozíciók és eljárások |
ES2935476T3 (es) | 2015-02-20 | 2023-03-07 | Sage Therapeutics Inc | Esteroides neuroactivos, composiciones y usos de los mismos |
JP2018530585A (ja) | 2015-10-16 | 2018-10-18 | マリナス ファーマシューティカルズ インコーポレイテッド | ナノ粒子を含む注射可能な神経ステロイド製剤 |
WO2017156103A1 (en) * | 2016-03-08 | 2017-09-14 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
CA3030420A1 (en) * | 2016-07-11 | 2018-01-18 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
IL264129B2 (en) * | 2016-07-11 | 2024-05-01 | Sage Therapeutics Inc | C20, C17 and C21 converted neuroactive steroids and methods of using them |
KR102518846B1 (ko) | 2016-08-11 | 2023-04-05 | 오비드 테라퓨틱스 인크. | 간질 장애의 치료를 위한 방법 및 조성물 |
US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
JP2021505608A (ja) | 2017-12-08 | 2021-02-18 | セージ セラピューティクス, インコーポレイテッド | CNS障害を処置するためのジュウテリウム化された21−[4−シアノ−ピラゾール−1−イル]−19−ノル−プレガン−3.α−オール−20−オン誘導体 |
CN114805462A (zh) * | 2018-02-11 | 2022-07-29 | 江苏豪森药业集团有限公司 | 一种甾族类衍生物调节剂及其制备方法和应用 |
CN109503694A (zh) * | 2018-11-21 | 2019-03-22 | 苏州闻天医药科技有限公司 | 一种新型gabaa受体调节剂及其用途 |
US11266662B2 (en) | 2018-12-07 | 2022-03-08 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of postpartum depression |
EP3911331A4 (en) * | 2019-01-14 | 2023-01-18 | Beijing Xuanyi Pharmasciences Co., Ltd. | TETRAZOLONE SUBSTITUTED STEROIDS AND USE THEREOF |
BR112021024033A2 (pt) | 2019-05-31 | 2022-02-08 | Sage Therapeutics Inc | Esteroides neuroativos e suas composições |
MX2022001553A (es) | 2019-08-05 | 2022-04-18 | Marinus Pharmaceuticals Inc | Ganaxolona para su uso en el tratamiento del estado epileptico. |
WO2021023213A1 (zh) | 2019-08-07 | 2021-02-11 | 上海翰森生物医药科技有限公司 | 一种甾族类衍生物调节剂的盐及其晶型 |
US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
MX2022006014A (es) | 2019-12-06 | 2022-06-22 | Marinus Pharmaceuticals Inc | Ganaxolona para uso en el tratamiento del complejo de esclerosis tuberosa. |
IL304080A (en) | 2021-01-28 | 2023-08-01 | Sage Therapeutics Inc | Use of neuroactive steroids to treat sexual dysfunction |
KR20240037975A (ko) * | 2021-07-28 | 2024-03-22 | 세이지 테라퓨틱스, 인크. | 신경활성 스테로이드의 결정질 형태 |
WO2023164387A1 (en) | 2022-02-28 | 2023-08-31 | Sage Therapeutics, Inc. | Neuroactive steroids for treatment of gastrointestinal diseases or conditions |
WO2024026337A1 (en) | 2022-07-27 | 2024-02-01 | Sage Therapeutics, Inc. | Crystalline forms of a neuroactive steroid |
WO2024059608A1 (en) | 2022-09-15 | 2024-03-21 | Sage Therapeutics, Inc. | Deuterated neuroactive steroids |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3634717A1 (de) * | 1986-10-11 | 1988-04-14 | Dynamit Nobel Ag | Verfahren zur herstellung von 5-methyltetrazol |
US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
US5939545A (en) * | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
IL112638A (en) * | 1994-02-14 | 2003-10-31 | Cocensys Inc | 3alpha-HYDROXYLATED PREGNANE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
WO1998005337A1 (en) * | 1996-08-01 | 1998-02-12 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
WO2000066614A1 (en) * | 1999-04-29 | 2000-11-09 | Purdue Pharma Ltd. | 3α-HYDROXY-3β METHOXYMETHYL-21-HETEROCYCLE SUBSTITUTED STEROIDS WITH ANESTHETIC ACTIVITY |
WO2004036372A2 (en) * | 2002-10-15 | 2004-04-29 | Medtronic Inc. | Scoring of sensed neurological signals for use with a medical device system |
US7729773B2 (en) * | 2005-10-19 | 2010-06-01 | Advanced Neuromodualation Systems, Inc. | Neural stimulation and optical monitoring systems and methods |
CA3152410A1 (en) * | 2011-10-14 | 2013-04-18 | Sage Therapeutics, Inc. | 3,3-disubstituted 19-nor pregnane compounds, compositions, and uses thereof for the treatment of cns related disorders |
SI3705488T1 (sl) * | 2014-05-29 | 2022-10-28 | Sage Therapeutics, Inc. | Nevroaktivni steroidi, sestavki in uporaba le-teh |
ES2808855T3 (es) * | 2014-10-16 | 2021-03-02 | Sage Therapeutics Inc | Composiciones y métodos para tratar trastornos del SNC |
-
2015
- 2015-05-29 SI SI201531879T patent/SI3705488T1/sl unknown
- 2015-05-29 TW TW104117532A patent/TW201625661A/zh unknown
- 2015-05-29 PL PL15799762T patent/PL3149018T3/pl unknown
- 2015-05-29 HU HUE20171670A patent/HUE059829T2/hu unknown
- 2015-05-29 PT PT157997628T patent/PT3149018T/pt unknown
- 2015-05-29 ES ES20171670T patent/ES2927007T3/es active Active
- 2015-05-29 SG SG11201609813XA patent/SG11201609813XA/en unknown
- 2015-05-29 SI SI201531252T patent/SI3149018T1/sl unknown
- 2015-05-29 EP EP15799762.8A patent/EP3149018B1/en active Active
- 2015-05-29 KR KR1020247014858A patent/KR20240066304A/ko active Application Filing
- 2015-05-29 SG SG10201803812TA patent/SG10201803812TA/en unknown
- 2015-05-29 PL PL20171670.1T patent/PL3705488T3/pl unknown
- 2015-05-29 IL IL292461A patent/IL292461B2/en unknown
- 2015-05-29 DK DK20171670.1T patent/DK3705488T3/da active
- 2015-05-29 RS RS20220848A patent/RS63554B1/sr unknown
- 2015-05-29 HR HRP20221294TT patent/HRP20221294T1/hr unknown
- 2015-05-29 LT LTEP15799762.8T patent/LT3149018T/lt unknown
- 2015-05-29 RU RU2019126637A patent/RU2019126637A/ru unknown
- 2015-05-29 US US15/314,565 patent/US20180179247A1/en active Pending
- 2015-05-29 AU AU2015266447A patent/AU2015266447A1/en not_active Abandoned
- 2015-05-29 PT PT201716701T patent/PT3705488T/pt unknown
- 2015-05-29 EP EP22187660.0A patent/EP4144746A1/en active Pending
- 2015-05-29 KR KR1020167036320A patent/KR102494061B1/ko active IP Right Grant
- 2015-05-29 EP EP20171670.1A patent/EP3705488B1/en active Active
- 2015-05-29 WO PCT/CN2015/080216 patent/WO2015180679A1/en active Application Filing
- 2015-05-29 MX MX2016015532A patent/MX2016015532A/es unknown
- 2015-05-29 DK DK15799762.8T patent/DK3149018T3/da active
- 2015-05-29 LT LTEP20171670.1T patent/LT3705488T/lt unknown
- 2015-05-29 CN CN202111131937.9A patent/CN114133423A/zh active Pending
- 2015-05-29 AR ARP150101717A patent/AR100691A1/es active IP Right Grant
- 2015-05-29 CA CA2949720A patent/CA2949720A1/en active Pending
- 2015-05-29 JP JP2016569716A patent/JP6652934B2/ja active Active
- 2015-05-29 IL IL304033A patent/IL304033A/en unknown
- 2015-05-29 IL IL248948A patent/IL248948B/en unknown
- 2015-05-29 RU RU2016151727A patent/RU2699359C2/ru active
- 2015-05-29 CN CN201580039652.9A patent/CN106661078A/zh active Pending
- 2015-05-29 HU HUE15799762A patent/HUE050028T2/hu unknown
- 2015-05-29 CN CN202110905603.6A patent/CN114369135A/zh active Pending
- 2015-05-29 ES ES15799762T patent/ES2805598T3/es active Active
- 2015-05-29 RS RS20200799A patent/RS60529B1/sr unknown
- 2015-05-31 JO JOP/2015/0132A patent/JO3691B1/ar active
-
2016
- 2016-11-24 PH PH12016502342A patent/PH12016502342A1/en unknown
- 2016-11-25 MX MX2023004352A patent/MX2023004352A/es unknown
- 2016-11-25 MX MX2021005106A patent/MX2021005106A/es unknown
- 2016-11-25 MX MX2021005099A patent/MX2021005099A/es unknown
-
2019
- 2019-12-09 AU AU2019279910A patent/AU2019279910B2/en active Active
-
2020
- 2020-01-24 JP JP2020009771A patent/JP6892936B2/ja active Active
- 2020-01-31 US US16/778,975 patent/US20200165291A1/en not_active Abandoned
- 2020-07-17 HR HRP20201126TT patent/HRP20201126T1/hr unknown
- 2020-07-27 CY CY20201100683T patent/CY1124109T1/el unknown
- 2020-11-10 US US17/094,783 patent/US20210061849A1/en not_active Abandoned
- 2020-11-13 US US17/097,569 patent/US20210061850A1/en not_active Abandoned
-
2021
- 2021-03-25 AR ARP210100747A patent/AR121661A2/es unknown
- 2021-05-28 JP JP2021089953A patent/JP7386204B2/ja active Active
- 2021-06-28 AU AU2021204410A patent/AU2021204410B2/en active Active
-
2023
- 2023-07-10 JP JP2023113247A patent/JP2023123878A/ja active Pending
- 2023-10-06 US US18/482,079 patent/US20240076310A1/en active Pending
- 2023-12-19 AU AU2023285755A patent/AU2023285755A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL292461A (en) | Neuroactive steroids, preparations and their uses | |
IL285703A (en) | Neuroactive steroids, preparations and their uses | |
HK1258616A1 (zh) | 神經活性類固醇、組合物、及其用途 | |
HK1225977B (zh) | 神經活性類固醇、組合物和其用途 | |
EP3258939A4 (en) | Neuroactive steroids, compositions, and uses thereof | |
HK1220472A1 (zh) | 神經活性類固醇、組合物、及其用途 | |
HUE053900T2 (hu) | Neuroaktív szteroidok, kompozíciók, és azok alkalmazásai | |
IL250568A0 (en) | Anti-methanogenic preparations and their uses |